4D-150 shows up to 98% injection reduction in wet AMD; Phase 3 4FRONT expected Q1 2025

4D Molecular Therapeutics, Inc.

Phase 2b Broad (n=30): 89% annualized injection reduction, 80% with 0 or 1 injection, 70% injection-free at 52 weeks.
Phase 2b Recently Diagnosed (n=15): 98% injection reduction, 100% with 0 or 1 injection, 87% injection-free.
Safety: 2.8% rate of 4D-150-related IOI (2 of 71); no hypotony, endophthalmitis, or vasculitis observed.
Planned Phase 3 4FRONT-1 (N=500) to start Q1 2025; primary endpoint noninferiority BCVA vs aflibercept; RMAT and PRIME designations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.